
Independent thinking. Direct access. Commercial discipline.
A Copenhagen-based pharmaceutical business development and transaction advisory firm, originating, structuring and executing cross-border partnerships.
Where European standards meet global demand
We work directly with pharmaceutical manufacturers, Marketing Authorisation Holders, asset owners and private equity-backed healthcare groups.
Unlike high-volume brokers that circulate unvetted product lists, Generix works on a selective, mandate-focused model. We filter out market noise and deliver counterparties with verified technical capability, regulatory compliance and genuine intent.


Rigour before introductions
Every engagement starts with an objective assessment of product viability, regulatory status, pricing dynamics and supply readiness.
By validating alignment before any outreach, we protect our partners' reputation, preserve confidentiality and shorten deal cycles.
How we work
Selective origination
Quality over volume. We engage only on opportunities with a clear rationale, verified assets and executable timelines.
Confidentiality & IP protection
Dossier data, pricing and M&A mandates are sensitive. Every exchange is governed by NDA/CDA protocols.
Regulatory-commercial alignment
Partner selection accounts for GMP status, dossier completeness and local authorisation requirements.
Partnership longevity
We structure agreements for sustainable performance, repeat supply and multi-market scale, not one-off deals.
Connecting pharmaceutical value across borders
To be the trusted strategic BD partner for pharmaceutical companies seeking disciplined international expansion, efficient portfolio monetisation and resilient supply partnerships.
Explore our expertise
Accelerate your next transaction.
Whether you are expanding your therapeutic portfolio, monetising existing dossiers or entering new international territories, Generix brings the reach and discipline to execute.

